Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane

Authors


Abstract

Objective

To explore the potential of dexrazoxane to suppress subclinical cardiotoxicity in MS patients receiving mitoxantrone.

Methods

An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48mg/m2 cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography.

Results

No patient experienced symptoms of heart failure. Patients receiving dexrazoxane, which is cardioprotective for anthracyclines, exhibited a significantly lesser decline in left ventricular ejection fraction (mean change, −3.80% vs −8.55%, p < 0.001).

Interpretation

These results support a cardioprotective effect of dexrazoxane in mitoxantrone treated multiple sclerosis patients. Ann Neurol 2006;59:206–209

Ancillary